Mount Tam Biotechnologies Seeks FDA Approval For Lupus Study

Date Posted:
Jun 22, 2016

Novato-based Mount Tam Biotechnologies, which works closely with the Buck Institute for Research on Aging, is applying to the FDA to study an investigational drug to treat the immune disease lupus, which the Lupus Foundation of America estimates that 1.5 million Americans and 5 million people worldwide have lupus.

The company, which licenses R&D assets from the Buck Institute, and features Buck CEO Brian Kennedy as chairman of the board, plans to start manufacturing its TAM-01 drug for lupus shortly and plans human clinical trials. In September of 2015, Mount Tam used a reverse merger to become public, a move that was recently profiled in detail in the North Bay Business Journal.

For more information, please visit the Mount Tam Biotechnologies website.